Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ODC1 | P11926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11885389 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL3072771 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL16438222 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL10196037 | 1.00 | CA2 (0.41) | CA2ADRB2ADRB1ADRB3ODC1 | |
| SCHEMBL4863760 | 1.00 | — | — | |
| SCHEMBL317775 | 0.90 | — | — | |
| SCHEMBL30130365 | 0.88 | CA2 (0.34) | CA2ADRB2ADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL1781746 | 0.87 | — | — | |
| SCHEMBL28880086 | 0.85 | CA2 (0.34) | CA2 | |
| SCHEMBL23647292 | 0.83 | CA2 (0.44) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | disclosed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | disclosed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | CA2 281/4885ADRB2 1452/4885ADRB1 2162/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | CA2 2378/4885ADRB2 266/4885ADRB1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.